Johnson & Johnson (JNJ)vsAlpha Teknova Inc (TKNO)
JNJ
Johnson & Johnson
$257.02
-0.24%
HEALTHCARE · Cap: $614.36B
TKNO
Alpha Teknova Inc
$6.53
+16.40%
HEALTHCARE · Cap: $270.75M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 234169% more annual revenue ($97.93B vs $41.80M). JNJ leads profitability with a 21.5% profit margin vs -41.1%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
TKNO
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-84.8%
Fair Value
$139.37
Current Price
$257.01
$117.64 premium
Intrinsic value data unavailable for TKNO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 0.9%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -26.4% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : TKNO
The strongest argument for TKNO centers on Debt/Equity. Revenue growth of 13.1% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : TKNO
The primary concerns for TKNO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while TKNO is a turnaround play — different risk/reward profiles.
TKNO carries more volatility with a beta of 0.63 — expect wider price swings.
TKNO is growing revenue faster at 13.1% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 28/100), backed by strong 21.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Alpha Teknova Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Alpha Teknova Inc (TKNO) is a leading entity in the synthetic biology industry, specializing in the development of essential biological reagents and supplements that facilitate advancements in life sciences research and biomanufacturing. The company's innovative offerings are integral to high-demand sectors, including vaccine development, cell and gene therapy, and diagnostic testing, underscoring its commitment to quality and superior customer support. With a robust biotechnology foundation and a focus on innovation, Alpha Teknova is well-positioned to capitalize on growth opportunities within the rapidly evolving life sciences market, enhancing its appeal to institutional investors seeking strategic investments.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?